Research records indexed for Setmelanotide
This page carries 12 of the 220 records that the literature query returned for Setmelanotide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 208 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Setmelanotide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial pmid:39549719 | 2025 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Obesity; Hyperphagia; Pro-Opiomelanocortin; Alpha-MSH; Receptor, Melanocortin, Type 4. |
| Patient and caregiver experiences with a patient-support program for setmelanotide treatment of patients with Bardet-Biedl syndrome pmid:40484968 | 2025 | research-article | other | Not stated | Indexed as research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Bardet-Biedl Syndrome; Alpha-MSH; Quality Of Life; Caregivers; Surveys And Questionnaires. |
| Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome pmid:39919037 | 2025 | Clinical Trial, Phase III, research-article | human trial | Not stated | Indexed as clinical trial, phase iii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Bardet-Biedl Syndrome; Obesity; Alpha-MSH; Receptor, Melanocortin, Type 4; Body Mass Index. |
| Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial pmid:38697184 | 2024 | Clinical Trial, Phase II, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase ii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Hypothalamic Diseases; Obesity; Alpha-MSH; Receptor, Melanocortin, Type 4; Body Mass Index. |
| MC4R Variants Modulate α-MSH and Setmelanotide Induced Cellular Signaling at Multiple Levels pmid:38567654 | 2024 | research-article | other | Not stated | Indexed as research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Alpha-MSH; Receptor, Melanocortin, Type 4; Cyclic AMP; Signal Transduction. |
| Investigation of setmelanotide, an MC4R agonist, for obesity in individuals with Smith-Magenis syndrome pmid:38987029 | 2024 | Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't | other | Not stated | Indexed as research support, n.i.h., intramural, research support, non-u.s. gov't. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Body Weight; Weight Loss; Alpha-MSH; Receptor, Melanocortin, Type 4. |
| Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results pmid:36647077 | 2023 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Bardet-Biedl Syndrome; Obesity; Hyperphagia; Alpha-MSH; Quality Of Life. |
| Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity pmid:36722447 | 2023 | research-article, Review | other | Not stated | Indexed as research-article, review. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Adrenal Insufficiency; Hyperphagia; Pro-Opiomelanocortin; Alpha-MSH. |
| Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome pmid:36961653 | 2023 | Research Support, Non-U.S. Gov't, research-article | other | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Bardet-Biedl Syndrome; Alpha-MSH; Quality Of Life; Caregivers. |
| Could setmelanotide be the game-changer for acquired hypothalamic obesity? pmid:38239988 | 2023 | brief-report, Randomized Controlled Trial | human trial | Not stated | Indexed as brief-report, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Hypothalamic Diseases; Obesity; Obesity, Morbid; Alpha-MSH; Prospective Studies. |
| Aqueous remote loading of setmelanotide in poly(lactic-co-glycolic acid) microspheres for long-term obesity treatment pmid:37678438 | 2023 | Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural | rodent | Not stated | Indexed as research support, non-u.s. gov't, research support, n.i.h., extramural. study model from MeSH "Mice". subject headings: Obesity; Disease Models, Animal; Body Weight; Glycols; Lactic Acid. |
| An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome pmid:37013719 | 2023 | research-article | other | Not stated | Indexed as research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Bardet-Biedl Syndrome; Obesity; Pro-Opiomelanocortin; Alpha-MSH. |
Where this page sits
Compound page: Setmelanotide. Class: Melanocortin receptor peptides.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 11993702, Setmelanotide. PubChem, National Library of Medicine (2026). pubchem:11993702
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA213793. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:setmelanotide
- Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-α-MSH and setmelanotide. Cell research (2021). pmid:34561620
- RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. The Journal of clinical endocrinology and metabolism (2015). pmid:25675384
- Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Molecular metabolism (2017). pmid:29031731
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. The lancet. Diabetes & endocrinology (2020). pmid:33137293
- Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes, obesity & metabolism (2020). pmid:32627316
- Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. The lancet. Diabetes & endocrinology (2022). pmid:36356613
- Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide. Journal of the Endocrine Society (2022). pmid:35528826
- Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet journal of rare diseases (2023). pmid:36647077
- Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. The lancet. Diabetes & endocrinology (2024). pmid:38697184
- Setmelanotide: First Approval. Drugs (2021). pmid:33638809
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.